AstraZeneca 'pushed drug for untested uses'

Firm on defensive after documents support patients' law suit over Seroquel

AstraZeneca launched a public relations push to get doctors to prescribe its best-selling psychiatric drug Seroquel for a string of uses that were not approved by safety regulators, according to a damning internal document released yesterday.

The UK's second biggest drug maker is being sued by 16,000 patients in the US for "spinning, skewing and concealing" information on the drug's potential side-effects, including diabetes and weight gain, and lawyers unearthed emails and strategy documents showing what they say are repeated violations of the law.

The company was forced on to the defensive yesterday after more than 230 internal documents were made public, supporting a legal assault that wil cost it hundreds of millions of dollars if successful.

In particular, the material shows that AstraZeneca worked hard in the early years of this decade to turn Seroquel into a blockbuster drug with sales far beyond its originally approved market as a treatment for adult schizophrenia. It would be several more years before clinical trials showed it was safe and effective in a broader range of illnesses, including bipolar disorder, yet the company quickly made a substantial part of its revenues from doctors prescribing the drug for uses not officially sanctioned.

Regulators such as the Food and Drug Administration in the US carefully set out what claims can be made for every drug, and control the exact wording of the drug's label. Companies promoting products for unapproved uses face large fines.

A public relations strategy document emailed around the company in February 2001 by a brand manager, Alison Wilkie, said that "2001 communications will focus on increasing the existing off-label usage of Seroquel in [bipolar disorder], estimated to account for around 20 per cent of current prescriptions and growing strongly."

The documents also show that David Brennan, then head of AstraZeneca's US business and now chief executive of the company, was alerted by an employee that salesmen were targeting doctors who specialised in treating children, despite the fact that Seroquel has never been approved for use by minors.

A spokesman for AstraZeneca said that anti-psychotic drugs have always been widely prescribed by doctors for uses beyond the official label, and regulators are well aware that they are. "In that robust off-label environment, we sought to expand the approved indications for Seroquel," he said. "These documents do not advocate the inappropriate promotion of Seroquel."



Before the employee raised the issue to Mr. Brennan, AstraZeneca, as part of its ongoing compliance efforts, had made extensive efforts to monitor and align its sales calls with physicians who were prescribing Seroquel on label.



Other documents show AstraZeneca keeping a close eye on the legal line between promoting clinical studies of Seroquel in disorders for which it is not yet approved and outright marketing of the drug for off-label use by the commercial department. One 2004 email said that slides prepared in connection with a study involving off-label use of Seroquel were "financed outside of Commercial for obvious legal reasons". On another document, the minutes of a meeting about doctors' attitudes to anti-psychotic drugs, a brand manager had scrawled that the sales force could "grease the skids" for Seroquel's use as a treatment for dementia.

Ed Blizzard, attorney for 6,000 Seroquel patients suing AstraZeneca, said: "These strategy plans are not accidental. They are approved by people at the highest levels of the company. This is not just a few people, this is the strategy of the company." Mr Blizzard is leading the legal effort to win compensation for patients who claim that Seroquel caused their diabetes or medical complications due to their weight gain.

AstraZeneca has had two cases dismissed due to lack of evidence, but the first trial is expected in June. The company says there is no scientific evidence Seroquel causes diabetes and it is committed to a strong defence effort, taking each individual case on its merits.

Start your day with The Independent, sign up for daily news emails
PROMOTED VIDEO
ebooks
ebooksA year of political gossip, levity and intrigue from the sharpest pen in Westminster
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Selby Jennings: Oil Operations

Highly Competitive: Selby Jennings: Our client, a leading European Oil trading...

The Jenrick Group: Night Shift Operations Manager

£43500 per annum + pension + holidays: The Jenrick Group: Night Shift Operatio...

SThree: Trainee Recruitment Consultant - LONDON

£20000 - £25000 per annum + OTE £40,000 + Car + Pension: SThree: SThree are a ...

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + OTE £35K: SThree: We consistently strive to be the...

Day In a Page

Isis in Iraq: Yazidi girls killing themselves to escape rape and imprisonment by militants

'Jilan killed herself in the bathroom. She cut her wrists and hanged herself'

Yazidi girls killing themselves to escape rape and imprisonment
Ed Balls interview: 'If I think about the deficit when I'm playing the piano, it all goes wrong'

Ed Balls interview

'If I think about the deficit when I'm playing the piano, it all goes wrong'
He's behind you, dude!

US stars in UK panto

From David Hasselhoff to Jerry Hall
Grace Dent's Christmas Quiz: What are you – a festive curmudgeon or top of the tree?

Grace Dent's Christmas Quiz

What are you – a festive curmudgeon or top of the tree?
Nasa planning to build cloud cities in airships above Venus

Nasa planning to build cloud cities in airships above Venus

Planet’s surface is inhospitable to humans but 30 miles above it is almost perfect
Surrounded by high-rise flats is a little house filled with Lebanon’s history - clocks, rifles, frogmen’s uniforms and colonial helmets

Clocks, rifles, swords, frogmen’s uniforms

Surrounded by high-rise flats is a little house filled with Lebanon’s history
Return to Gaza: Four months on, the wounds left by Israel's bombardment have not yet healed

Four months after the bombardment, Gaza’s wounds are yet to heal

Kim Sengupta is reunited with a man whose plight mirrors the suffering of the Palestinian people
Gastric surgery: Is it really the answer to the UK's obesity epidemic?

Is gastric surgery really the answer to the UK's obesity epidemic?

Critics argue that it’s crazy to operate on healthy people just to stop them eating
Homeless Veterans appeal: Christmas charity auction Part 2 - now LIVE

Homeless Veterans appeal: Christmas charity auction

Bid on original art, or trips of a lifetime to Africa or the 'Corrie' set, and help Homeless Veterans
Pantomime rings the changes to welcome autistic theatre-goers

Autism-friendly theatre

Pantomime leads the pack in quest to welcome all
The week Hollywood got scared and had to grow up a bit

The week Hollywood got scared and had to grow up a bit

Sony suffered a chorus of disapproval after it withdrew 'The Interview', but it's not too late for it to take a stand, says Joan Smith
From Widow Twankey to Mother Goose, how do the men who play panto dames get themselves ready for the performance of a lifetime?

Panto dames: before and after

From Widow Twankey to Mother Goose, how do the men who play panto dames get themselves ready for the performance of a lifetime?
Thirties murder mystery novel is surprise runaway Christmas hit

Thirties murder mystery novel is surprise runaway Christmas hit

Booksellers say readers are turning away from dark modern thrillers and back to the golden age of crime writing
Anne-Marie Huby: 'Charities deserve the best,' says founder of JustGiving

Anne-Marie Huby: 'Charities deserve the best'

Ten million of us have used the JustGiving website to donate to good causes. Its co-founder says that being dynamic is as important as being kind
The botanist who hunts for giant trees at Kew Gardens

The man who hunts giants

A Kew Gardens botanist has found 25 new large tree species - and he's sure there are more out there